Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Merck
Medtronic
Colorcon
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

RHOFADE Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Rhofade, and when can generic versions of Rhofade launch?

Rhofade is a drug marketed by Aclaris and is included in one NDA. There are six patents protecting this drug.

This drug has twenty-one patent family members in twelve countries.

The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.

Drug patent expirations by year for RHOFADE
Drug Prices for RHOFADE

See drug prices for RHOFADE

Recent Clinical Trials for RHOFADE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Actavis Inc.Phase 3
Teva Pharmaceuticals USAPhase 3

See all RHOFADE clinical trials

Pharmacology for RHOFADE
Synonyms for RHOFADE
1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol hydrochloride
2-(3-Hydroxy-2,6-dimethyl-4-t-butylbenzyl)-2-imidazoline hydrochloride
2-(3-HYDROXY-2,6-DIMETHYL-4-TERT-BUTYLBENZYL)-2-IMIDAZOLINE HYDROCHLORIDE
2-(4-t-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium chloride
2-(4-t-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoliniumchloride
2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium chloride
2-(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)-4,5-dihydro-1H-imidazol-1-ium chloride
2-[3-Hydroxy-2,6-dimethyl-4-t-butyl-benzyl]-2-imidazoline
2,6-Dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline hydrochloride
2,6-dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazolinehydrochlori
2,6-Dimethyl-4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline hydrochloride
2315-02-8
3-[(4,5-Dihydro-
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-phenol hydrochloride
315O028
4-Way Nasal Spray
6-(tert-butyl)-3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-2,4-dimethylphenol hydrochloride
6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-phenohydrochloride
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol hydrochloride
6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenolhydrochloride
6-tert-butyl-3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-2,4-dimethylphenol hydrochloride
6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol hydrochloride
6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol monohydrochloride
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-phenol hydrochloride
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol hydrochloride
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride
AB2000600
AC1L24Z6
Afrazine
Afrin
Afrin hydrochloride
afrinhydrochloride
AKOS000280887
AN-10106
Anefrin nasal
BEEDODBODQVSIM-UHFFFAOYSA-N
Benzedrex Nasal Spray 12 Hour
CCG-40216
CHEBI:7863
CHEMBL1200791
CS-2533
CTK8G2231
D01022
Dristan Long Lasting Nasal Mist
DTXSID80177729
Duration 12 Hour Nasal Spray
Duration Nasal Spray
EINECS 219-015-0
EU-0100903
FT-0082561
HMS1568N09
HMS1920D18
HY-B0427A
iliadinhydrochloride
K89MJ0S5VY
KB-221830
KS-5222
LLiadin Mini Paediatric
Lliadine
LP00903
LS-104147
MCULE-1133105377
MFCD00017208
MFCD00058147
MLS000038040
MLS002222207
MolPort-000-709-375
Nafrine hydrochloride
Nasivin
Nasivine
NCGC00094218-01
NCGC00094218-02
NCGC00094218-03
NCGC00094218-04
NCGC00094218-05
NCGC00261588-01
Neo-Synephrine 12 Hour
Neo-Synephrine 12 Hour NTZ
Neonabel
Nostrilla
NSC-757254
NSC757254
O 2378
Ocuclear
Ocuclear (TN)
Opera_ID_32
Operil
Oximetazoline HCl
Oxymetazoline (hydrochloride)
Oxymetazoline chloride
Oxymetazoline HCl
Oxymetazoline hydrochloride
Oxymetazoline hydrochloride (JAN/USP)
Oxymetazoline hydrochloride [USAN:JAN]
Oxymetazoline hydrochloride [USAN:USP:JAN]
Oxymetazoline hydrochloride, >=99%, solid
Oxymetazoline hydrochloride, analytical standard
Oxymetazoline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Oxymetazoline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Oxymetazoline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Oxymetazoline Hydrochloride,(S)
Pharmakon1600-01500453
Phenol, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride
Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, hydrochloride
Prestwick_373
Rhfade (TN)
Sch 9384
SCH-9384
SCHEMBL41247
Sinex
Sinex VapoSpray Moisturizing 12-Hour Decongestant UltraFine Mist
SMR000059324
SPECTRUM1500453
SR-01000002705
SR-01000002705-2
SR-01000002705-4
SR-01000002705-7
St. Joseph Nasal Spray for Children
Sudafed OM
SW196632-3
Tox21_500903
UNII-K89MJ0S5VY
V0297
Vicks Sinex
Visine L.R
Visine L.R.
W-107424
Paragraph IV (Patent) Challenges for RHOFADE
Tradename Dosage Ingredient NDA Submissiondate
RHOFADE CREAM;TOPICAL oxymetazoline hydrochloride 208552 2019-06-20

US Patents and Regulatory Information for RHOFADE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aclaris RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Aclaris RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Aclaris RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
McKinsey
Harvard Business School
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.